18 CAMPUS BLVD., NEWTOWN SQUARE, PA
Arrivent Unveils Firmonertinib Study Results for EGFR Mutant Lung Cancer at 2025 Lung Cancer Conference
Reports Second Quarter 2025 Financial Results
Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Arrivent Reports Positive Firmonertinib Study Results for EGFR Mutant Lung Cancer
Shareholder votes
Reports First Quarter 2025 Financial Results
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Certificate
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership